(VIANEWS) – Xylem (XYL), LTC Properties (LTC), Edwards Lifesciences (EW) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Xylem (XYL)
37.6% sales growth and 7.47% return on equity
Xylem Inc., together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions for the water and wastewater applications in the United States, Europe, the Asia Pacific, and internationally. It operates through three segments: Water Infrastructure, Applied Water, and Measurement & Control Solutions. The Water Infrastructure segment offers various products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the Flygt, Godwin, Sanitaire, Leopold, Wedeco, and Xylem Vue brand names for the transportation and treatment of water. The Applied Water segment provides pumps, valves, heat exchangers, controls, and dispensing equipment systems under the Goulds Water Technology, Bell & Gossett, A-C Fire Pump, Standard Xchange, Lowara, Jabsco, Xylem Vue, and Flojet brand names for residential and commercial building services, and industrial water applications. The Measurement & Control Solutions segment offers smart meters, networked communication devices, data analytics, test equipment, controls, sensor devices, software and managed services, and critical infrastructure services; and software and services, including cloud-based analytics, remote monitoring and data management, leak detection, condition assessment, asset management, and pressure monitoring solutions, as well as testing equipment. This segment sells its products under the Pure Technologies, Sensus, Smith Blair, WTW, Xylem Vue, and YSI brand names. The company markets and sells its products through a network of direct sales force, resellers, distributors, and value-added solution providers. Xylem Inc. was formerly known as ITT WCO, Inc. and changed its name to Xylem Inc. in May 2011. Xylem Inc. was incorporated in 2011 and is headquartered in Washington, District of Columbia.
Earnings Per Share
As for profitability, Xylem has a trailing twelve months EPS of $2.45.
PE Ratio
Xylem has a trailing twelve months price to earnings ratio of 47.16. Meaning, the purchaser of the share is investing $47.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.47%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 4.3% and 5.1%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Xylem’s EBITDA is 68.84.
2. LTC Properties (LTC)
24.8% sales growth and 9.61% return on equity
LTC is a real estate investment trust (REIT) investing in seniors housing and health care properties primarily through sale-leasebacks, mortgage financing, joint-ventures and structured finance solutions including preferred equity and mezzanine lending. LTC holds 180 investments in 27 states with 29 operating partners. The portfolio is comprised of approximately 50% seniors housing and 50% skilled nursing properties.
Earnings Per Share
As for profitability, LTC Properties has a trailing twelve months EPS of $1.91.
PE Ratio
LTC Properties has a trailing twelve months price to earnings ratio of 16.67. Meaning, the purchaser of the share is investing $16.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.61%.
Yearly Top and Bottom Value
LTC Properties’s stock is valued at $31.84 at 10:22 EST, way below its 52-week high of $38.94 and above its 52-week low of $30.50.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Feb 19, 2024, the estimated forward annual dividend rate is 2.28 and the estimated forward annual dividend yield is 7.24%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 4.5% and a drop 43.8% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.5%, now sitting on 189.8M for the twelve trailing months.
3. Edwards Lifesciences (EW)
7.1% sales growth and 22.06% return on equity
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Earnings Per Share
As for profitability, Edwards Lifesciences has a trailing twelve months EPS of $2.34.
PE Ratio
Edwards Lifesciences has a trailing twelve months price to earnings ratio of 36.91. Meaning, the purchaser of the share is investing $36.91 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.06%.
Yearly Top and Bottom Value
Edwards Lifesciences’s stock is valued at $86.38 at 10:22 EST, under its 52-week high of $94.87 and way above its 52-week low of $60.57.
4. Grand Canyon Education (LOPE)
6.9% sales growth and 31.45% return on equity
Grand Canyon Education, Inc. provides education services to colleges and universities in the United States. The company's technology services include learning management system, internal administration, infrastructure, and support services; academic services comprises program and curriculum, faculty and related training and development, class scheduling, and skills and simulation lab sites; and counseling services and support include admission, financial aid, and field experience and other counseling services. It also offers marketing and communication services, such as lead acquisition, digital communications strategy, brand identity, market research, media planning and strategy, video, and business intelligence and data science; and back-office services comprising finance and accounting, human resources, audit, and procurement services. The company supports healthcare education programs for 27 universities. Grand Canyon Education, Inc. was founded in 1949 and is based in Phoenix, Arizona.
Earnings Per Share
As for profitability, Grand Canyon Education has a trailing twelve months EPS of $6.37.
PE Ratio
Grand Canyon Education has a trailing twelve months price to earnings ratio of 20.53. Meaning, the purchaser of the share is investing $20.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.45%.
5. Cemex, S.A.B. de C.V. Sponsored ADR (CX)
6.6% sales growth and 3.99% return on equity
CEMEX, S.A.B. de C.V., together with its subsidiaries, produces, markets, distributes, and sells cement, ready-mix concrete, aggregates, clinker, and other construction materials worldwide. The company also offers various complementary construction products, including asphalt products; concrete blocks; roof tiles; architectural products; concrete pipes for storm and sanitary sewers applications; and other precast products, such as rail products, concrete floors, box culverts, bridges, drainage basins, barriers, and parking curbs. In addition, it provides building solutions for housing projects, pavement projects, and green building consultancy services; cement trade maritime services; and information technology solutions. The company operates approximately 2,000 retail stores in approximately 600 cities. CEMEX, S.A.B. de C.V. was founded in 1906 and is headquartered in San Pedro Garza GarcÃa, Mexico.
Earnings Per Share
As for profitability, Cemex, S.A.B. de C.V. Sponsored ADR has a trailing twelve months EPS of $-1.46.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.99%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 241.7% and 13.3%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Cemex, S.A.B. de C.V. Sponsored ADR’s EBITDA is 32.91.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.5%, now sitting on 17.04B for the twelve trailing months.
